Navicixizumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.

**Synonyms:** - Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric Monoclonal Antibody, Bispecific - NAVICIXIZUMAB - OMP 305B83 - OMP-305B83 - OMP305B83